How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer

CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

(2013) Kenneth F. Schulz   ANNALS OF INTERNAL MEDICINE

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

(2012) Florentia Fostira et al.   BREAST CANCER RESEARCH AND TREATMENT

The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions

(2011) Fiona CHIONH et al.   Asia-Pacific Journal of Clinical Oncology

Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: Design of a multicenter randomized clinical trial

(2011) Marijke R Wevers et al.   BMC CANCER

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers

(2011) K Metcalfe et al.   BRITISH JOURNAL OF CANCER

Expanding DNA diagnostic panel testing: is more better?

(2011) Eric W Klee et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast and ovarian cancer genetic counseling?

(2011) Elvira M. Zilliacus et al.   GENETICS IN MEDICINE

Management of Women With BRCA Mutations

(2011) Nadine Tung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy

(2010) Lori J. Pierce et al.   BREAST CANCER RESEARCH AND TREATMENT

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

(2010) D G R Evans et al.   BRITISH JOURNAL OF CANCER

500 Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival?

(2010) B.A.M. Heemskerk-Gerritsen et al.   EJC SUPPLEMENTS

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

(2010) Susan M. Domchek   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

BRCA mutations in the management of breast cancer: the state of the art

(2010) Steven A. Narod   Nature Reviews Clinical Oncology

Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study

(2008) Noah D. Kauff et al.   JOURNAL OF CLINICAL ONCOLOGY